FDA approves first targeted therapy for bladder cancer

Author(s):

On April 12, the FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic bladder cancer that has a susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following previous platinum-containing chemotherapy.

Read more at fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here